To pursue the clinical value of FDX1 in ccRCC, we first correlated the FDX1 IHC intensity with the histological T stage and tumor grade of ccRCC tumors in the micro-array (n = 51, we excluded 11 tumors because their T stage and grade were not confidently confirmed by a pathologist). This evidence concerns the gene FDX1 and nonpapillary renal cell carcinoma.